Bristol-Myers Squibb Company stock page - price, fundamentals, dividends - iOCharts

BMY

60.50
-0.81 (-1.32%)
Bristol-Myers Squibb Company (NYSE, USD)
Healthcare >
Drug Manufacturers-General
Market cap
135.09B
Ent value
198.87B
Price/Sales
3.18
Price/Book
3.59
Div yield
3.24%
Div growth
8.98%
Growth years
12
FCF payout
30.64%
Trailing P/E
-
Forward P/E
7.56
PEG
-
EPS growth
10.90%
1 year return
2.08%
3 year return
-0.53%
5 year return
1.70%
10 year return
7.40%
Last updated: 2021-09-20

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open60.64
Daily high61.38
Daily low60.16
Daily Volume15.2M
All-time high76.77
1y analyst estimate75.37
Beta0.62
EPS (TTM)-4.06
Dividend per share1.96
Ex-div date1 Jul 2021
Next earnings date27 Oct 2021

Downside potential

Loading...
Downside potential data
BMYS&P500
Current price drop from All-time high-21.19%-4.23%
Highest price drop-76.73%-56.47%
Date of highest drop16 Oct 20089 Mar 2009
Avg drop from high-35.23%-11.47%
Avg time to new high41 days12 days
Max time to new high4176 days1805 days

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share1.96
Dividend yield3.24%
Payout frequencyQuarterly
Maximum yield3.88%
Average yield2.99%
Minimum yield2.32%
Discount to avg yield7.75%
Upside potential8.40%
Yield as % of max yield83.51%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.24%
Current yield distribution19.21%
Yield at 100% (Min)2.32%
Yield at 90%2.59%
Yield at 80%2.72%
Yield at 50% (Median)2.98%
Yield at 20%3.23%
Yield at 10%3.42%
Yield at 0% (Max)3.88%

Dividend per share

Loading...
Dividend per share data
Years of growth12 years
CCC statusDividend Contender
Dividend per share1.96
Payout frequencyQuarterly
Ex-div date1 Jul 2021
EPS (TTM)-4.06
EPS (1y forward)8.00
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BMYS&P500
DGR MR8.89%7.68%
DGR TTM9.09%-2.66%
DGR 3 years13.65%5.82%
DGR 5 years8.98%6.23%
DGR 10 years9.08%9.64%
DGR 15 years4.88%6.71%
Time since last change announced286 days
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM-45.20%30.64%
Average--
Forward24.50%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF9.61
Price to FCF10.16
Price to EBITDA38.50
EV to EBITDA56.67

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.18
Price to Book3.59
EV to Sales4.68

FINANCIALS

Per share

Loading...
Per share data
Current share count2.23B
EPS (TTM)-4.06
FCF per share (TTM)5.99

Income statement

Loading...
Income statement data
Revenue (TTM)42.52B
Gross profit (TTM)30.75B
Operating income (TTM)2.18B
Net income (TTM)-9.02B
EPS (TTM)-4.06
EPS (1y forward)8.00

Margins

Loading...
Margins data
Gross margin (TTM)72.31%
Operating margin (TTM)5.12%
Profit margin (TTM)-21.20%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash10.98B
Net receivables8.66B
Total current assets27.11B
Goodwill20.52B
Intangible assets50.82B
Property, plant and equipment6.61B
Total assets112.44B
Accounts payable2.97B
Short/Current long term debt46.28B
Total current liabilities17.33B
Total liabilities74.76B
Shareholder's equity37.67B
Net tangible assets-33.74B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)14.05B
Capital expenditures (TTM)753.00M
Free cash flow (TTM)13.30B
Dividends paid (TTM)4.08B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-23.80%
Return on Assets-7.61%
Return on Invested Capital-10.18%
Cash Return on Invested Capital15.02%
COMPANY DETAILS
BMY (Bristol-Myers Squibb Company) company logo
Marketcap
135.09B
Marketcap category
Large-cap
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Employees
30250
SEC filings
CEO
Giovanni Caforio
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
September 21, 2021
More than 150 colleagues from 14 EU countries just finished cycling 3,000 km in our Country 2 Country 4 Cancer (C2C4C) event to raise awareness and much-needed donations for cancer research. It’s m...
September 21, 2021
Bristol Myers (BMY) application for fixed-dose combination of LAG-3-blocking antibody relatlimab and immuno- oncology Opdivo gets priority review in the United States.
September 20, 2021
Bristol Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.32% move from the prior day.
September 20, 2021
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.
September 20, 2021
PRINCETON, N.J., September 20, 2021--U.S. FDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination...
September 18, 2021
When a biotech company develops a drug candidate that can help millions of people fight a monstrous disease such as Alzheimer's, it will certainly gain attention from scientists, the news media, and t...
September 17, 2021
Gritstone bio Inc (NASDAQ: GRTS) has announced results with its SLATE v1 product ("off-the-shelf" shared neoantigen immunotherapy). The therapy is in combination with Bristol-Myers Squibb Co's (NYSE: ...
September 17, 2021
PRINCETON, N.J., September 17, 2021--BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal....
September 16, 2021
In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.23, marking a -1.24% move from the previous day.
September 16, 2021
Bristol Myers Squibb Co (NYSE: BMY) announced Opdivo (nivolumab) plus Yervoy (ipilimumab) long-term survival data in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC...
Next page